Robert Peter Gale

ORCID: 0000-0002-9156-1676 · 2 papers in corpus · active 2018-2022

Study types

  • article 2
article 2022
·doi:10.1002/hon.3026

Ruxolitinib is a safe and effective therapy of myeloproliferative neoplasm-associated (MPN) myelofibrosis. However, often there are dose reductions and/or therapy interruptions because of therapy-related adverse events (AEs), especially ane…

article 2018
·doi:10.1038/s41408-017-0029-4

Abstract Low-dose thalidomide and prednisone alone or combined are effective therapies in some persons with primary myelofibrosis (PMF) and anemia with or with RBC transfusion dependence. Danazol is also effective in some persons with PMF a…